These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 16408431

  • 21. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
    Dumoulin A, Hill GS, Montseny JJ, Meyrier A.
    Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
    [Abstract] [Full Text] [Related]

  • 22. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.
    Hofstra JM, Wetzels JF.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3534-8. PubMed ID: 18559961
    [Abstract] [Full Text] [Related]

  • 23. Idiopathic membranous nephropathy: diagnosis and treatment.
    Fervenza FC, Sethi S, Specks U.
    Clin J Am Soc Nephrol; 2008 May; 3(3):905-19. PubMed ID: 18235148
    [Abstract] [Full Text] [Related]

  • 24. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y, Pucino F, Balow JE, Austin HA.
    Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
    [Abstract] [Full Text] [Related]

  • 25. Does treatment with corticosteroids and cyclosporine reduce transglutaminase type 2 expression in the renal tissue of patients with membranous nephropathy?
    Papasotiriou M, Kalliakmani P, Huang L, Gerolymos M, Goumenos DS, Johnson TS.
    Nephron Clin Pract; 2012 Aug; 121(1-2):c60-7. PubMed ID: 23107829
    [Abstract] [Full Text] [Related]

  • 26. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
    Maas R, Hofstra JM, Wetzels JF.
    Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
    [Abstract] [Full Text] [Related]

  • 27. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
    Yang S, Xie L, Xue W, Yin A, Lu W.
    Nephrology (Carlton); 2013 Sep; 18(9):615-22. PubMed ID: 23889815
    [Abstract] [Full Text] [Related]

  • 28. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?
    Ahuja M, Goumenos D, Shortland JR, Gerakis A, Brown CB.
    Am J Kidney Dis; 1999 Sep; 34(3):521-9. PubMed ID: 10469864
    [Abstract] [Full Text] [Related]

  • 29. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.
    Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B.
    N Engl J Med; 1989 Jan 05; 320(1):8-13. PubMed ID: 2642605
    [Abstract] [Full Text] [Related]

  • 30. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
    Li X, Lv R, He Q, Li H, Du X, Lin W, Li Q, He X, Wang S, Chen J.
    J Nephrol; 2008 Jan 05; 21(4):584-91. PubMed ID: 18651550
    [Abstract] [Full Text] [Related]

  • 31. Prognosis of untreated patients with idiopathic membranous nephropathy.
    Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G.
    N Engl J Med; 1993 Jul 08; 329(2):85-9. PubMed ID: 8510707
    [Abstract] [Full Text] [Related]

  • 32. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy.
    Kalliakmani P, Koutroulia E, Sotsiou F, Vlachojannis JG, Goumenos DS.
    Nephrology (Carlton); 2010 Dec 08; 15(8):762-7. PubMed ID: 21175962
    [Abstract] [Full Text] [Related]

  • 33. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy.
    Kosmadakis G, Filiopoulos V, Smirloglou D, Skarlas P, Georgoulias C, Michail S.
    Ren Fail; 2010 Jun 08; 32(5):566-71. PubMed ID: 20486839
    [Abstract] [Full Text] [Related]

  • 34. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
    Shearman JD, Yin ZG, Aarons I, Smith PS, Woodroffe AJ, Clarkson AR.
    Clin Nephrol; 1988 Dec 08; 30(6):320-9. PubMed ID: 3243041
    [Abstract] [Full Text] [Related]

  • 35. The impact of sex in primary glomerulonephritis.
    Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, Troyanov S, Genes, Gender and Glomerulonephritis Group.
    Nephrol Dial Transplant; 2008 Jul 08; 23(7):2247-53. PubMed ID: 18182409
    [Abstract] [Full Text] [Related]

  • 36. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
    Busch M, Gerth J, Ott U, Schip A, Haufe CC, Gröne HJ, Wolf G.
    Med Klin (Munich); 2008 Jul 15; 103(7):519-24. PubMed ID: 18604487
    [Abstract] [Full Text] [Related]

  • 37. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure.
    Warwick GL, Geddes CG, Boulton-Jones JM.
    Q J Med; 1994 Apr 15; 87(4):223-9. PubMed ID: 8208913
    [Abstract] [Full Text] [Related]

  • 38. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy.
    Laluck BJ, Cattran DC.
    Am J Kidney Dis; 1999 Jun 15; 33(6):1026-32. PubMed ID: 10352189
    [Abstract] [Full Text] [Related]

  • 39. Increased remission of early stage membranous nephropathy on long-term treatment with corticosteroid.
    Funabiki K, Tomino Y, Shirato I, Yoshida M, Koide H.
    Nihon Jinzo Gakkai Shi; 1992 Sep 15; 34(9):997-1001. PubMed ID: 1479738
    [Abstract] [Full Text] [Related]

  • 40. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine.
    Mok CC, Ying KY, Yim CW, Ng WL, Wong WS.
    Lupus; 2009 Oct 15; 18(12):1091-5. PubMed ID: 19762384
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.